Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TuHURA Biosciences, Inc./NV

Get SEC filing alerts via email and in your feed for TuHURA Biosciences, Inc./NV

HURA

TuHURA Biosciences, Inc./NV

About TuHURA Biosciences, Inc./NV

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing innovative cancer therapies. Its core focus is on innate immune agonists and tumor microenvironment modulators, including bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting myeloid-derived suppressor cells. The company aims to overcome resistance to immunotherapies, enhance immune responses, and expand treatment options for various cancers through proprietary technologies and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TuHURA Biosciences, Inc./NV

1
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports $7.5 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports Increased Operating Losses and Financial Challenges for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports $7.1 Million Net Loss in Latest Quarter, Highlights Acquisition of Kineta

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports $9.5 Million Net Loss in Q2 2025, Increases Operating Expenses Following Kineta Merger

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports Increased Net Loss of $6.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TuHURA Biosciences, Inc./NV TuHURA Biosciences Reports $22.6 Million Net Loss for Fiscal Year 2024, Focuses on Cancer Vaccine Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TuHURA Biosciences, Inc./NV Kintara Therapeutics Reports Financial Challenges, Net Loss, and Doubts Over Going Concern Following Merger and Reverse Stock Split

Via official filing (AI summary) | over 1 year ago | 0 comments